secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0000875045-24-000030
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen Q3 GAAP EPS $2.66, revenue $2.466B; raises FY2024 Non-GAAP EPS guidance to $16.10-$16.60
--------------------------------------------------------------------------------

- Q3 2024 revenue $2.466B (-3% YoY); GAAP diluted EPS $2.66 vs ($0.47) in Q3 2023.
- Non-GAAP diluted EPS $4.08 (-6% YoY); FY2024 Non-GAAP EPS guidance raised to $16.10-$16.60 (~11% growth at midpoint).
- LEQEMBI global in-market sales ~$67M (US $39M); other launches delivered sequential revenue growth.
- Dapirolizumab pegol Phase 3 met primary endpoint in SLE; second Phase 3 study to initiate in 2024.
- Nusinersen higher dose showed statistically significant improvement; global regulatory submissions planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000087504524000030/0000875045-24-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000087504524000030/biib-20241030.htm
  HTML page:      https://secwatch.observer/filing/0000875045-24-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer